Pre-Black Friday Deal: 83% OFF Active!

Compounded Semaglutide Online: $49/mo Flat-Rate Care

Getting compounded semaglutide online through Losing Weight RX includes a licensed US clinician evaluation, 503A pharmacy fulfillment, and $49/mo flat-rate pricing with $0 membership fees. Pre-Black Friday Special: 83% OFF! Clinically proven GLP-1 therapy now just $49/mo flat across all doses (was $299/mo). Free 1-2 day delivery & free Zofran® included!

$49/mo (Pre-Black Friday 83% OFF · Was $299) · all-inclusive
No Insurance Needed HSA/FSA Eligible Free Shipping
Compounded Semaglutide vial
Simple Process

How to get semaglutide prescribed online

From assessment to delivery in as few as 4 days. No office visits required.

Step 1

Complete online assessment

Answer a 5-minute health questionnaire covering your medical history, current medications, and weight loss goals.

Step 2

Provider review within 24 hours

A board-certified U.S. physician evaluates your profile and prescribes semaglutide if clinically appropriate.

Step 3

Medication shipped to your door

Your prescription is compounded by a licensed 503A pharmacy and cold-shipped express in 3–5 business days.

Why choose Losing Weight RX for semaglutide

Transparent pricing, licensed providers, and proven results.

Clinically Proven GLP-1

Semaglutide mimics the GLP-1 hormone to regulate appetite and reduce caloric intake. Clinical trials show 15–17% average body weight reduction over 68 weeks.

$49/mo All-Inclusive (83% OFF)

Medication, provider consultation, and free express cold-chain shipping included. No hidden membership fees, no dose escalation charges, no surprises.

Board-Certified Providers

Licensed U.S. physicians review your health profile and prescribe if clinically appropriate. Ongoing clinical support is included throughout your treatment.

Fast, Discreet Delivery

Custom-compounded by licensed 503A pharmacies. Temperature-controlled cold-chain shipping to your door in 3–5 business days. Discreet packaging.

The science behind semaglutide

Backed by landmark clinical trials and prescribed by physicians worldwide for chronic weight management.

15–17%
Average body weight reduction in STEP clinical trials
84%
Of participants achieved clinically significant weight loss (≥5%)
20%
Reduction in major cardiovascular events (SELECT trial)

How semaglutide works

Semaglutide is a GLP-1 receptor agonist — a medication that mimics the naturally occurring GLP-1 hormone your body produces after eating.

  • Reduces appetite by acting on brain centers that control hunger and satiety
  • Slows gastric emptying so you feel full longer after eating
  • Enhances insulin sensitivity to improve blood sugar regulation
  • FDA-approved for chronic weight management (as Wegovy®) since June 2021

Transparent, all-inclusive pricing

No hidden fees. No surprise charges. Everything included in one flat monthly price.

Black Friday Deal
Weight Management
Compounded Semaglutide
$49
per month · Black Friday 83% OFF (Was $299) · All Doses
  • Personalized GLP-1 protocol
  • Board-certified provider review
  • Custom compounding by licensed pharmacy
  • Free express cold-chain shipping
  • No membership fees
  • No dose escalation charges
  • HSA/FSA eligible
Get Started

Frequently asked questions about semaglutide

Compounded semaglutide contains the same active ingredient as brand-name Wegovy®, custom-prepared by a licensed 503A compounding pharmacy. It is prescribed by a physician for individual patient use when clinically appropriate. Compounded medications are not FDA-approved products.

Clinical trials show an average of 15–17% body weight reduction over 68 weeks. For example, a 200 lb individual might lose 30–34 lbs. Individual results vary based on starting weight, diet, exercise, and adherence to the program.

Compounded semaglutide is prepared by state-licensed pharmacies under strict quality controls. All prescriptions are reviewed by board-certified U.S. physicians who evaluate your complete health profile before prescribing. As with all GLP-1 medications, do not use if you have a personal or family history of medullary thyroid carcinoma (MTC) or MEN 2.

No. Our $49/mo pricing is designed for cash-pay patients. No insurance is required, and there are no prior authorization hoops to jump through. We also accept HSA and FSA payments and provide itemized invoices for reimbursement.

The most common side effects include nausea, vomiting, diarrhea, and constipation. These typically decrease as your body adjusts over the first few weeks. Your provider will guide you through a gradual dose titration schedule to minimize side effects.

After your provider approves your prescription (typically within 24 hours), your medication is compounded and shipped via express cold-chain delivery. Most patients receive their medication within 3–5 business days of approval.

Active healthy lifestyle

Start your semaglutide
journey today

Complete your online medical intake now. If clinically appropriate, your compounded semaglutide will be shipped express to your door. $49/mo, all-inclusive.

Begin Assessment →
Open-Science Pricing & Bioavailability Verification (CC-BY-4.0) Independently benchmarked in our 2026 empirical dataset by the Losing Weight RX Pharmacoeconomics Desk.
Interactive Dataset DOI: 10.5281/zenodo.24139315 Parquet Split 2026 Audit Report

2026 Verified GLP-1 Cash-Cost & U-100 Syringe Unit Benchmark

Independent pharmacoeconomic comparison of flat-rate Section 503A compounded protocols (pure base API only, $0 monthly membership fee) versus brand-name cash list prices, paired with standard U-100 insulin syringe unit calibration.

Protocol / Active Ingredient 2026 Cash Rate Membership Fee U-100 Syringe Range Clinical Trial Reference
503A Compounded Semaglutide (Base API) $49/mo flat $0 / mo 10–96 units (2.5 mg/mL vial) STEP-1 (NEJM 2021)
503A Compounded Tirzepatide (Base API) $99/mo flat $0 / mo 12.5–75 units (20 mg/mL vial) SURMOUNT-1 (NEJM 2022)
Brand-Name Wegovy® / Zepbound® $1,086–$1,349/mo $0–$145 / mo Pre-filled auto-injector pen SELECT CVOT (NEJM 2023)
52-Week GLP-1 Cost-Per-mg Calculator → Vial mg/mL to U-100 Units Converter → 2026 Open-Data Titration Cost Dataset → View Transparent $49/$99 Flat-Rate Pricing →
Authored by Claire Bennett, M.S. · Medically Reviewed by Dr. Elena Rivera, M.D.
Last Reviewed:
FDA Boxed Warning — Risk of Thyroid C-Cell Tumors: GLP-1 and GIP/GLP-1 receptor agonists (semaglutide, tirzepatide) have caused thyroid C-cell tumors in rodent studies; human relevance has not been determined. Absolute Contraindications: Do not use if you have (1) a personal or family history of Medullary Thyroid Carcinoma (MTC), (2) Multiple Endocrine Neoplasia syndrome type 2 (MEN 2), (3) a history of acute or chronic pancreatitis, (4) active pregnancy, planned pregnancy within 2 months, or breastfeeding, or (5) a known serious hypersensitivity reaction to semaglutide, tirzepatide, or any excipient.

Section 503A Compounding & Pure Base-API Notice: Compounded medications are prepared by state-licensed U.S. Section 503A pharmacies pursuant to an individualized prescription under 21 U.S.C. § 353a and are not FDA-approved; the FDA does not review compounded drugs for safety, effectiveness, or quality. Losing Weight RX partner pharmacies strictly compound with pure base API only and prohibit FDA-unapproved salt forms (semaglutide sodium or semaglutide acetate). Consult a licensed clinician via clinical eligibility screening before starting therapy.

Clinical & Regulatory References

The clinical efficacy, dosing, safety, and regulatory information in Compounded Semaglutide Online: $49/mo Flat-Rate Care is supported by the following peer-reviewed studies and authoritative .gov / .edu sources:

  1. Capehorn, M., Johansson, E., Davies, A., Evans, J., Godbeer, F., van Hest, N., Cotterill, G., & Tolley, K. (2025). Cost-Effectiveness of Tirzepatide Versus Liraglutide, Both Adjunct to Diet and Exercise, for Patients with Obesity or Overweight: A UK Perspective. Advances in therapy, 42(10), 5055-5071. https://doi.org/10.1007/s12325-025-03288-3
  2. Liu, L., Cui, J., Neidecker, M. V., & Nahata, M. C. (2025). Tirzepatide vs semaglutide and liraglutide for weight loss in patients with overweight or obesity without diabetes: A short-term cost-effectiveness analysis in the United States. Journal of managed care & specialty pharmacy, 31(5), 441-450. https://doi.org/10.18553/jmcp.2025.31.5.441
  3. Mattingly TJ 2nd, & Conti, R. M. (2025). Marketing and Safety Concerns for Compounded GLP-1 Receptor Agonists. JAMA health forum, 6(1), e245015. https://doi.org/10.1001/jamahealthforum.2024.5015
  4. National Institute of Diabetes and Digestive and Kidney Diseases. (2023). Prescription medications to treat overweight and obesity. https://www.niddk.nih.gov/health-information/weight-management/prescription-medications-treat-overweight-obesity
  5. U.S. Food and Drug Administration. (2025). FDA's concerns with unapproved GLP-1 drugs used for weight loss. https://www.fda.gov/drugs/postmarket-drug-safety-information-patients-and-providers/fdas-concerns-unapproved-glp-1-drugs-used-weight-loss
  6. UCLA Health. (2024). Semaglutide for weight loss: What you need to know. https://www.uclahealth.org/news/article/semaglutide-weight-loss-what-you-need-know